- Datum11.12.2025
- Uhrzeit17:00 - 17:30 Uhr
- Veranstalter
stock3
Idorsia AG Aktie
Verkaufen
Kaufen
Idorsia AG Chart
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Idorsia AG Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (SIX)
-6,40 %
Intraday
-8,45 %
1 Woche
-16,43 %
1 Monat
255,84 %
Seit Jahresbeginn
285,38 %
1 Jahr
-80,59 %
3 Jahre
-89,11 %
5 Jahre
Passender Service zu Idorsia AG
Webinar zu Idorsia AG
Kursinformationen (SIX)
- Tagestief / Hoch (Fr)-
- 52W-Tief / Hoch (Fr)0,633-4,850
- Jahrestief / Hoch (Fr)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Idorsia AG
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2027 (e) |
Termine von Idorsia AG
- Feb26Idorsia AGQ4 2025 Earnings Release
- Apr28Idorsia AGQ1 2026 Earnings Release
- Jul28Idorsia AGQ2 2026 Earnings Release
Beschreibung
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
